Semin Neurol 2005; 25(1): 64-68
DOI: 10.1055/s-2005-867075
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Sleep Disorders in Multiple Sclerosis

W. Elon Fleming1 , Charles P. Pollak2
  • 1Sleep Disorders Center, Island Hospital, Anacortes, Washington
  • 2Sleep Laboratory, Cornell Medical Center, New York, New York
Further Information

Publication History

Publication Date:
29 March 2005 (online)

ABSTRACT

Sleep disorders are pervasive in patients with multiple sclerosis (MS) although clinically underrecognized by most physicians. The most common sleep disorders seen in patients with MS include insomnia, nocturnal movement disorders, sleep-disordered breathing, narcolepsy, and rapid eye movement sleep behavior disorder. Factors that influence the quality of sleep in this patient population include pain, nocturia, depression, medication effect, location of lesions, and disease severity. Disrupted sleep has the potential to cause daytime somnolence, increased fatigue, and nonrefreshing sleep, and it may be associated with dangerous respiratory events. Awareness and treatment of these conditions is vital to improving health and quality of life in patients with MS.

REFERENCES

  • 1 Tachibana N, Howard R S, Hirsch N P, Miller D H, Moseley I F, Fish D. Sleep problems in multiple sclerosis.  Eur Neurol. 1994;  34 320-323
  • 2 Saunders J, Whitham R, Schaumann B. Sleep disturbance, fatigue, and depression in multiple sclerosis.  Neurology. 1991;  41(suppl 1) 320
  • 3 Leo G J, Rao M, Bernardin L. Sleep disturbances in multiple sclerosis.  Neurology. 1991;  41(suppl 1) 320
  • 4 Achiron A, Barak Y, Gabbay U. Sleep disturbance in multiple sclerosis: clinical and neuroradiologic correlations related to disease activity.  J Neuroimmunol. 1995;  56-63(suppl 1) 57
  • 5 Ford D E, Kamerow D B. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention?.  JAMA. 1989;  262 1479-1484
  • 6 Sadovnick A D, Remick R A, Allen J et al.. Depression and multiple sclerosis.  Neurology. 1996;  46 628-632
  • 7 Feinstein A, Kartsounis L D, Miller D H, Youl B D, Ron M A. Clinically isolated lesions of the type seen in multiple sclerosis: a cognitive, psychiatric, and MRI follow up study.  J Neurol Neurosurg Psychiatry. 1992;  55 869-876
  • 8 Fruehwald S, Loeffler-Stastka H, Eher R, Saletu B, Baumhackl U. Depression and quality of life in multiple sclerosis.  Acta Neurol Scand. 2001;  104 257-261
  • 9 Rae-Grant A D, Eckert N J, Bartz S, Reed J F. Sensory symptoms of multiple sclerosis: a hidden reservoir of morbidity.  Mult Scler. 1999;  5 179-183
  • 10 Ferini-Strambi L, Filippi M, Martinelli V et al.. Nocturnal sleep study in multiple sclerosis: correlations with clinical and brain magnetic resonance imaging findings.  J Neurol Sci. 1994;  125 194-197
  • 11 Coleman R M, Pollak C P, Weitzman E D. Periodic movements in sleep (nocturnal myoclonus): relation to sleep disorders.  Ann Neurol. 1980;  8 416-421
  • 12 Ekbom K A. Restless legs: a clinical study.  Acta Med Scand Suppl. 1945;  158 1
  • 13 Strang R R. The symptom of restless legs.  Med J Aust. 1967;  1 1211-1213
  • 14 Lavigne G J, Montplaisir J Y. Restless legs syndrome and sleep bruxism: prevalence and association among Canadians.  Sleep. 1994;  17 739-743
  • 15 Coleman R M, Bliwise D L, Sajben N et al.. Epidemiology of periodic limb movements during sleep. In: Guilleinault C, Lugaresi E Sleep/Wake Disorders: Natural History, Epidemiology and Long Term Evolution New York; Raven Press 1988: 217-229
  • 16 Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria.  Mov Disord. 1997;  12 61-65
  • 17 Montplaisir J, Lapierre O, Warnes H, Pelletier G. The treatment of the restless leg syndrome with or without periodic leg movements in sleep.  Sleep. 1992;  15 391-395
  • 18 Lugaresi E, Cirignotta F, Coccagna G, Montagna P. Nocturnal myoclonus and restless legs syndrome.  Adv Neurol. 1986;  43 295-307
  • 19 Desautels A, Turecki G, Montplaisir J, Sequeira A, Verner A, Rouleau G A. Identification of a major susceptibility locus for restless legs syndrome on chromosome 12q.  Am J Hum Genet. 2001;  69 1266-1270
  • 20 Bonati M T, Ferini-Strambi L, Aridon P, Oldani A, Zucconi M, Casari G. Autosomal dominant restless legs syndrome maps on chromosome 14q.  Brain. 2003;  126 1485-1492
  • 21 Onen S H, Alloui A, Gross A, Eschallier A, Dubray C. The effects of total sleep deprivation, selective sleep interruption and sleep recovery on pain tolerance thresholds in healthy subjects.  J Sleep Res. 2001;  10 35-42
  • 22 Solaro C, Uccelli M M, Guglieri P, Uccelli A, Mancardi G L. Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis.  Mult Scler. 2000;  6 192-193
  • 23 Amarenco G, Kerdraon J, Denys P. [Bladder and sphincter disorders in multiple sclerosis. Clinical, urodynamic and neurophysiological study of 225 cases].  Rev Neurol (Paris). 1995;  151 722-730
  • 24 Leo G J, Rao S M, Bernardin L. Sleep disturbance in multiple sclerosis.  Neurology. 1991;  41(suppl 1) 320 , (Abstract)
  • 25 Nuotio M, Tammela T L, Luukkaala T, Jylha M. Predictors of institutionalization in an older population during a 13-year period: the effect of urge incontinence.  J Gerontol A Biol Sci Med Sci. 2003;  58 756-762
  • 26 Valiquette G, Herbert J, Maede-D'Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial.  Arch Neurol. 1996;  53 1270-1275
  • 27 Rebif®. Product information, 2002
  • 28 Huber S, Spycher M, Lechner-Scott J, Bellaiche Y, Steck A J, Kappos L. [Multiple sclerosis: therapy with recombinant beta-1b interferon: initial results with 30 multiple sclerosis patients in northwest Switzerland].  Schweiz Med Wochenschr. 1996;  126 1475-1481
  • 29 Antonijevic I A, Steiger A. Depression-like changes of the sleep-EEG during high dose corticosteroid treatment in patients with multiple sclerosis.  Psychoneuroendocrinology. 2003;  28 780-795
  • 30 Patten S B, Fridhandler S, Beck C A, Metz L M. Depressive symptoms in a treated multiple sclerosis cohort.  Mult Scler. 2003;  9 616-620
  • 31 Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults.  N Engl J Med. 1993;  328 1230-1235
  • 32 Auer R N, Rowlands C G, Perry S F, Remmers J E. Multiple sclerosis with medullary plaques and fatal sleep apnea (Ondine's curse).  Clin Neuropathol. 1996;  15 101-105
  • 33 Wunderlin B W, Kesselring J, Ginzler H et al.. Fatigue in multiple sclerosis is not due to sleep apnea.  Eur J Neurol. 1997;  4 72-78
  • 34 Howard R S, Wiles C M, Hirsch N P, Loh L, Spencer G T, Newsom-Davis J. Respiratory involvement in multiple sclerosis.  Brain. 1992;  115 479-494
  • 35 Schrader H, Gotlibsen O B, Skomedal G N. Multiple sclerosis and narcolepsy/cataplexy in a monozygotic twin.  Neurology. 1980;  30 105-108
  • 36 Bonduelle M, Degos C. Symptomatic narcolepsies: a critical study. In: Guilleminault C, Dement WC, Passouant P Narcolepsy New York; Spectrum 1976: 322-325
  • 37 Langdon N, Welsh K I, van Dam M, Vaughan R W, Parkes D. Genetic markers in narcolepsy.  Lancet. 1984;  2 1178-1180
  • 38 Caballero A, Alves-Leon S, Papais-Alvarenga R, Fernandez O, Navarro G, Alonso A. DQB1*0602 confers genetic susceptibility to multiple sclerosis in Afro-Brazilians.  Tissue Antigens. 1999;  54 524-526
  • 39 Mignot E, Lin X, Arrigoni J et al.. DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans.  Sleep. 1994;  17(suppl 8) S60-S67
  • 40 Juji T, Satake M, Honda Y, Doi Y. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive.  Tissue Antigens. 1984;  24 316-319
  • 41 Duquette P, Decary F, Pleines J et al.. Clinical sub-groups of multiple sclerosis in relation to HLA: DR alleles as possible markers of disease progression.  Can J Neurol Sci. 1985;  12 106-110
  • 42 Younger D S, Pedley T A, Thorpy M J. Multiple sclerosis and narcolepsy: possible similar genetic susceptibility.  Neurology. 1991;  41 447-448
  • 43 Iseki K, Mezaki T, Oka Y et al.. Hypersomnia in MS.  Neurology. 2002;  59 2006-2007
  • 44 Billiard M, Besset A, Montplaisir J et al.. Modafinil: a double-blind multicentric study.  Sleep. 1994;  17(suppl 8) S107-S112
  • 45 Kato T, Kanbayashi T, Yamamoto K et al.. Hypersomnia and low CSF hypocretin-1 (orexin-A) concentration in a patient with multiple sclerosis showing bilateral hypothalamic lesions.  Intern Med. 2003;  42 743-745
  • 46 Rammohan K W, Rosenberg J H, Lynn D J, Blumenfeld A M, Pollak C P, Nagaraja H N. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study.  J Neurol Neurosurg Psychiatry. 2002;  72 179-183
  • 47 Scammell T E, Estabrooke I V, McCarthy M T et al.. Hypothalamic arousal regions are activated during modafinil-induced wakefulness.  J Neurosci. 2000;  20 8620-8628
  • 48 Tison F, Wenning G K, Quinn N P, Smith S J. REM sleep behaviour disorder as the presenting symptom of multiple system atrophy.  J Neurol Neurosurg Psychiatry. 1995;  58 379-380
  • 49 Uchiyama M, Isse K, Tanaka K et al.. Incidental Lewy body disease in a patient with REM sleep behavior disorder.  Neurology. 1995;  45 709-712
  • 50 Wright B A, Rosen J R, Buysse D J, Reynolds C F, Zubenko G S. Shy-Drager syndrome presenting as a REM behavioral disorder.  J Geriatr Psychiatry Neurol. 1990;  3 110-113
  • 51 Plazzi G, Montagna P. Remitting REM sleep behavior disorder as the initial sign of multiple sclerosis.  Sleep Med. 2002;  3 437-439

W. Elon FlemingM.D. 

Medical Director, Sleep Disorders Center, Island Hospital

1211 24th Street, Anacortes, WA 98221